Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

NCT05863351 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT05863351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05863351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 27, 2023
Completion date
August 31, 2028
Enrollment
472 (estimated)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, stage iv renal cell cancer ajcc v8